Journal
CARBOHYDRATE RESEARCH
Volume 380, Issue -, Pages 64-69Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.carres.2013.07.010
Keywords
Fucosylated chondroitin sulfate; HIV-1; Anti-HIV agent; HIV entry
Funding
- National Natural Science Foundation of China [81102483, 81001462, 81102372]
- 973 Program [2009CB522306]
- Key Scientific and Technological Program of China [2009ZX09501-029, 2012ZX10001-006, 2012ZX10001-007, 2012ZX09103-101-022]
- Key Scientific and Technological Program of Yunnan [2007BC006, 2010GA001, 2012BC011]
Ask authors/readers for more resources
Fucosylated chondroitin sulfate (FuCS-1) is a nontoxic and water-soluble depolymerized glycosaminoglycan obtained from the sea cucumber Thelenota ananas. Anti-HIV activities of FuCS-1 were evaluated in the present study. FuCS-1 was effective in blocking laboratory strain HIV-1(IIIB) entry and replication (4.26 mu g/mL and 0.73 mu g/mL, respectively), and inhibiting infection by clinic isolate HIV-1(KM018) and HIV-1(TC-2) (23.75 mu g/mL and 31.86 mu g/mL, respectively) as well as suppressing HIV-1 drug-resistant virus. It also inhibited HIV-2(ROD) and HIV-2(CBL-20) replication (100 mu g/mL). Notably, FuCS-1 showed highly effective antiviral activity against T-20-resistant strains (EC50 values ranging from 0.76 mu g/mL to 1.13 mu g/mL). Further studies indicated that FuCS-1 can potently bind the recombinant HIV-1 gp120 protein, but no inhibition of recombinant HIV-1 reverse transcriptase was observed. In conclusion, FuCS-1 inhibited several strains of HIV-1 replication with different potencies. These results suggest that FuCS-1 may possess great potential to be further developed as novel HIV-1 entry inhibitor for treatment of HIV/AIDS patients, particularly for those infected by T-20-resistant variants. (C) 2013 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available